- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01725035
Hepatic De Novo Lipogenesis (DNL)in the Pathogenesis of Hepatic Steatosis in Obese Youth (DNL)
The Role of Hepatic De Novo Lipogenesis (DNL) in the Pathogenesis of Hepatic Steatosis in Obese Children and Adolescents
Nonalcoholic Fatty Liver Disease (NAFLD) is becoming the most common cause of liver disease in pediatrics, but little is known about its pathophysiology in children. While studies in obese adults with hepatic steatosis have described an increased hepatic de novo lipogenesis (DNL) depending on the diet, there are no studies exploring the mechanisms by which excess hepatic triglycerides increases in obese youths, thus explaining the accompanying dyslipidemia and the metabolic syndrome. The central hypothesis of this study is that hepatic conversion of carbohydrates to lipid (DNL) is enhanced and associated with accumulation of excess liver fat, dyslipidemia and hepatic insulin resistance in obese youths with hepatic steatosis. The overall goal is to examine whether hepatic DNL is increased in obese youths with steatosis compared to matched controls without steatosis.
Hypotheses: Hepatic conversion of carbohydrates to lipid (DNL) is enhanced and is associated with accumulation of excess liver fat, dyslipidemia and hepatic insulin resistance in obese youths with hepatic steatosis.
Study Overview
Status
Conditions
Detailed Description
In this study obese youths, adolescents and young adults (12-30 years) will undergo MRI (magnetic resonance imaging) measurement of liver lipid content to determine hepatic fat content. They will undergo a sugary drink (75 grams of glucose and 25 grams of fructose) challenge and Hepatic de novo lipogenesis will be determined as the incorporation of deuterium, from deuterium labeled water (D2O), into plasma triglycerides. Subjects will undergo a 6 hours study assessing de novo lipogenesis, an oral glucose tolerance test, dual energy x-ray absorptiometry, magnetic resonance imaging, and Euglycemic-Hyperinsulinemic Clamp.
This study record has been re-opened in 2019 and updated to reflect any changes having remained open since its inception with the Yale University IRB and also having obtained additional funding though NIDDK.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Connecticut
-
New Haven, Connecticut, United States, 06510
- Yale University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
Cases will meet the following criteria:
- BMI higher than 75th percentile
- Hepatic fat fraction (the amount of fat into the liver) greater or equal than 5.5%
- Absence of any endocrinopathy
- Absence of any therapy with medication known to alter glucose metabolism
Controls will meet the following criteria:
- BMI higher than 75th percentile
- Hepatic fat fraction (the amount of fat into the liver) lower than 5.5%
- Absence of any endocrinopathy
- Absence of any therapy with medication known to alter glucose metabolism
- Absence of any therapy with medication known to alter glucose metabolism
Exclusion Criteria:
- BMI under the 75th percentile
- Hepatic fat fraction (the amount of fat into the liver) less than 5.5%
- Absence of any endocrinopathy
- Any therapy with medication known to alter glucose metabolism
Controls will meet the following criteria:
- BMI under the 75th percentile
- Hepatic fat fraction (the amount of fat into the liver) greater than or equal to 5.5%
- Any endocrinopathy
- Any therapy with medication known to alter glucose metabolism
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
Fatty liver
|
Non Fatty liver
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
de novo lipogenesis response to high carbohydrate meal in obese kids with fatty liver
Time Frame: Study visit 3
|
Study visit 3
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
de novo lipogenesis response to high carbohydrate meal in obese kids without fatty liver
Time Frame: Study visit 3
|
Study visit 3
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Sonia Caprio, M.D., Yale University
- Principal Investigator: Nicola Santoro, M.D./Ph.D,, Yale University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1008007192
- 11CRP5620013 (Other Grant/Funding Number: American Heart Association)
- 1R01DK114504-01A1 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fatty Liver
-
Shiraz University of Medical SciencesCompletedFatty Liver | Fatty Liver, NonalcoholicIran, Islamic Republic of
-
Hoffmann-La RocheCompletedFatty Liver, Non-alcoholic Fatty Liver Disease, NAFLDGermany, Austria
-
GenfitTerminatedNon-Alcoholic Fatty LiverNetherlands
-
Medical College of WisconsinENDRA Life Sciences, Inc.RecruitingFatty Liver | NAFLD | Non-Alcoholic Fatty Liver Disease | Non-alcoholic Steatohepatitis | Non-alcoholic Fatty Liver | NASH | Fatty Liver DiseaseUnited States
-
Cairo UniversityRecruitingNon-Alcoholic Fatty Liver DiseaseEgypt
-
Miriam Vos, MDImmuron Ltd.; Advanced MR Analytics ABCompletedNonalcoholic Fatty Liver Disease (NAFLD)United States
-
Nehal Abou SeadaCompletedNon-Alcoholic Fatty Liver Disease
-
HaEmek Medical Center, IsraelTerminatedPatients With Fatty Liver DiseaseIsrael
-
AB Biotics, SACompletedNon Alcoholic Fatty LiverMexico
-
University of L'AquilaRecruitingNAFLD- Non Alcoholic Fatty Liver DiseaseItaly